Keros Therapeutics (KROS) Other Non-Current Assets (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Other Non-Current Assets came in at $1.4 million in Q4 2025, down 3.38% YoY from $1.4 million in Q4 2024, and down 3.38% on a QoQ basis from $1.4 million in Q3 2025.
Keros Therapeutics (KROS) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Other Non-Current Assets data on file, last reported at $1.4 million in Q4 2025.
- Quarterly Other Non-Current Assets fell 3.38% year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (down 3.38% YoY) and the FY2025 annual result came in at $1.4 million, down 3.38% from the prior year.
- Other Non-Current Assets declined to $1.4 million in Q4 2025, from $1.4 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $2.1 million in Q4 2023 to a low of $115000.0 in Q1 2021.
- A 5-year average of $1.3 million and a median of $1.3 million in 2021 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2021 — Other Non-Current Assets soared 1054.78% — and 2024, when it retreated 29.39%.
- Tracing KROS's Other Non-Current Assets over 5 years: stood at $1.3 million in 2021, then changed by 0.0% to $1.3 million in 2022, then surged by 54.63% to $2.1 million in 2023, then dropped by 29.39% to $1.4 million in 2024, then fell by 3.38% to $1.4 million in 2025.
- The last three Other Non-Current Assets figures came in at $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | 1.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.45 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Mar 31, 2025 | 1.45 Mn |
| Dec 31, 2024 | 1.45 Mn |
| Sep 30, 2024 | 1.45 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Mar 31, 2024 | 1.21 Mn |
| Dec 31, 2023 | 2.05 Mn |
| Sep 30, 2023 | 1.21 Mn |
| Jun 30, 2023 | 1.33 Mn |
| Mar 31, 2023 | 1.33 Mn |
| Dec 31, 2022 | 1.33 Mn |
| Sep 30, 2022 | 1.33 Mn |
| Jun 30, 2022 | 1.33 Mn |
| Mar 31, 2022 | 1.33 Mn |
| Dec 31, 2021 | 1.33 Mn |
| Sep 30, 2021 | 1.33 Mn |
| Jun 30, 2021 | 115,000.00 |